Arrhythmogenic Right Ventricular Cardiomyopathy Clinical Trials

7 recruiting

Arrhythmogenic Right Ventricular Cardiomyopathy Trials at a Glance

8 actively recruiting trials for arrhythmogenic right ventricular cardiomyopathy are listed on ClinicalTrialsFinder across 6 cities in 8 countries. The largest study group is Not Applicable with 1 trial, with the heaviest enrollment activity in Rochester, New York, and Baltimore. Lead sponsors running arrhythmogenic right ventricular cardiomyopathy studies include Tenaya Therapeutics, Mayo Clinic, and Indiana University.

Browse arrhythmogenic right ventricular cardiomyopathy trials by phase

Treatments under study

About Arrhythmogenic Right Ventricular Cardiomyopathy Clinical Trials

Looking for clinical trials for Arrhythmogenic Right Ventricular Cardiomyopathy? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Arrhythmogenic Right Ventricular Cardiomyopathy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Arrhythmogenic Right Ventricular Cardiomyopathy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting

Mayo AVC Registry and Biobank

CardiomyopathiesCardiovascular DiseasesHeart Diseases+5 more
Mayo Clinic1,000 enrolled2 locationsNCT03049254
Recruiting
Not Applicable

Arrhythmogenic Activity During Exercise in ARVC Patients

Arrhythmogenic Right Ventricular Cardiomyopathy
Swiss Federal Institute of Technology120 enrolled1 locationNCT06040242
Recruiting
Phase 2

Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy

Arrhythmogenic CardiomyopathyArrhythmogenic Right Ventricular Cardiomyopathy
Hamilton Health Sciences Corporation120 enrolled17 locationsNCT06174220
Recruiting

Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis Transition

Hypertrophic CardiomyopathyMyocarditisHeart Failure With Preserved Ejection Fraction+4 more
University of Edinburgh290 enrolled1 locationNCT06409585
Recruiting

Pediatric Cardiomyopathy Mutation Analysis

CardiomyopathiesHypertrophic CardiomyopathyDilated Cardiomyopathy+3 more
Indiana University300 enrolled1 locationNCT02432092
Recruiting
Phase 1

Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC

Arrhythmogenic Right Ventricular Cardiomyopathy
Tenaya Therapeutics15 enrolled7 locationsNCT06228924
Recruiting

Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

Arrhythmogenic Right Ventricular Cardiomyopathy
Tenaya Therapeutics200 enrolled21 locationsNCT06311708
Recruiting

DZHK TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research Studies

AmyloidosisNon-ischemic CardiomyopathyArrhythmogenic Right Ventricular Cardiomyopathy+5 more
University Hospital Heidelberg2,040 enrolled1 locationNCT04265040